Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGNZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for LIGAND PHARMS BETA CVR (LGNZZ) centers on regulatory documents associated with Ligand Pharmaceuticals Incorporated, the issuer identified in related filings. Although LGNZZ itself is not detailed in the excerpted registration table, the name links it to the same company whose common stock trades under the symbol LGND on The Nasdaq Global Market.
One highlighted filing is a Form 8-K in which Ligand Pharmaceuticals Incorporated reports entry into a Third Amendment to its Credit Agreement. This document explains that the company, together with certain subsidiaries as guarantors, amended a credit facility with a group of lenders and Citibank, N.A. as administrative agent, swingline lender, and letter of credit issuer. The amendment extends the maturity date and adjusts a minimum consolidated EBITDA covenant, illustrating how the issuer’s direct financial obligations and covenants evolve over time.
On this page, users can review current reports on Form 8-K and related exhibits that describe material definitive agreements and the creation or modification of direct financial obligations. These filings provide insight into the company’s borrowing arrangements, financial maintenance requirements, and relationships with its lenders.
Stock Titan enhances access to these documents by pairing them with AI-powered summaries that explain the key points of lengthy agreements and technical disclosures. Instead of reading an entire amendment or credit agreement, users can rely on concise explanations that highlight the nature of the obligation, the roles of the parties, and the main covenant changes. Real-time updates from EDGAR help ensure that new filings, such as additional amendments or related exhibits, are incorporated as they become available.
Ligand Pharmaceuticals’ Chief Legal Officer and Secretary Andrew Reardon reported a set of planned insider transactions in company stock. On March 4, 2026, he exercised employee stock options for 5,000 shares of common stock and then sold 5,000 common shares in a series of open-market trades.
The sales were executed at weighted-average prices disclosed in ranges between approximately $197.58 and $208.97, under a Rule 10b5-1 trading plan adopted on November 24, 2025. After these transactions, Reardon directly holds 36,869 common shares and 54,444 options, with the underlying option grant vesting over time.
Ligand Pharmaceuticals’ Chief Financial Officer Octavio Espinoza reported option exercises and share sales in company stock. On March 4, 2026, he exercised employee stock options covering 2,073 shares of common stock and then sold 13,423 shares in open-market transactions.
The sales were executed at weighted-average prices generally between $198.37 and $208.95 pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on November 19, 2025. After these transactions, he directly owned 21,662 shares of Ligand common stock.
Ligand Pharmaceuticals director Stephen L. Sabba exercised a stock option for 2,034 common shares at $69.51 per share and on the same day sold 2,034 shares at $201.50 per share in an open-market transaction. He now directly holds 33,793 common shares.
Ligand Pharmaceuticals director John W. Kozarich reported open-market sales of company common stock. On March 2, 2026, he sold a total of 467 shares in six separate transactions under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1.
The reported weighted-average prices for these sales ranged from about $197 to $203 per share, based on detailed price ranges in the filing. After completing the transactions, Kozarich directly owned 42,720 shares of Ligand Pharmaceuticals common stock.
LGND reported a proposed sale of common stock on a Form 144 with transactions dated
Ligand Pharmaceuticals filed a Form S-3 shelf registration to offer up to
Ligand Pharmaceuticals Incorporated presents its annual report describing a royalty-focused biopharmaceutical business model built around capital deployment and licensing rather than in‑house drug development. The company aggregates royalty interests in mid‑ to late‑stage and commercial products, supported by infrastructure‑light platforms such as Captisol and NITRICIL.
Ligand highlights 12 major commercial royalty assets and more than 100 additional partnered programs, with 2025 royalty receipts of $176.9 million and GAAP income from royalty assets of $161.0 million. Key assets include Kyprolis, Qarziba, Filspari, Ohtuvayre, Capvaxive, Vaxneuvance, Rylaze, Evomela and Zelsuvmi.
During 2025, Ligand executed several investments and strategic transactions, including royalty financings with Castle Creek and Orchestra BioMed, a royalty and warrant deal with Arecor, and the Pelthos Transaction, which spun out Zelsuvmi into Pelthos Therapeutics while retaining equity, milestones and a 13% royalty. As of February 24, 2026, Ligand had 19,941,141 common shares outstanding.
Ligand Pharmaceuticals Incorporated reported a sharp turnaround in 2025, with total revenues and income of $268.1 million compared with $167.1 million in 2024, driven mainly by royalty growth and Pelthos-related contract revenue. GAAP net income reached $124.5 million, or $6.13 per diluted share, versus a net loss of $4.0 million, or $0.22 per share, the prior year.
Core adjusted net income rose to $165.1 million, or $8.13 per diluted share, from $108.5 million, or $5.74 per diluted share. Fourth quarter 2025 revenues and income were $59.7 million, up from $42.8 million, with GAAP diluted EPS of $2.12 compared with a loss of $1.64. Cash, cash equivalents and short‑term investments were $733.5 million at December 31, 2025.
For 2026, Ligand reaffirmed guidance for total revenue of $245 million to $285 million, including $200 million to $225 million of royalty revenue, $35 million to $40 million of Captisol revenue and $10 million to $20 million of contract revenue, and expects adjusted earnings per diluted share of approximately $8.00 to $9.00.